Onychomycosis Publications

Click on the title to see the full article:

A large-scale North American study of fungal isolates from nails the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns

A new classification system for grading the severity of onychomycosis Onychomycosis Severity Index

A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis

Clinical Trial Designs for Topical Antifungal Treatments of Onychomycosis and Implications on Clinical Practice

Current and Emerging Options in the Treatment of Onychomycosis

Diagnosis, clinical implications, and complications of onychomycosis

Effectiveness and Safety of Tavaborole, a Novel Boron-Based Molecule for the Treatment of Onychomycosis: Results from Two Phase 3 Studies

Efficacy and Safety of Onychomycosis Treatments An Evidence-Based Overview

Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies

Efinaconazole 10% solution in the treatment of toenail onychomycosis Two phase III multicenter, randomized, double-blind studies

Efinaconazole Topical Solution, 10% The Benefits of Treating Onychomycosis Early

Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults; a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies

Fluconazole for the treatment of onychomycosis An update

Making Strides in Preventing Onychomycosis Recurrence

Management strategies for onychomycosis in special patient populations

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail

Onchomycosis an overview

Onychomycosis and tinea pedis in patients with diabetes

Onychomycosis in special population. Focus on the diabetic

Onychomycosis information for patients

Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal

Prevalence and epidemiology of toenail onychomycosis in diabetic subjects A multicentre survey

Special patient populations Onychomycosis in the diabetic patient

The epidemiology, etiology, and pathophysiology of onychomycosis

Topical treatment of onychomycosis with efinaconazole solution 10%

Understanding Onychomycosis Treatment mechanisms of action and formulation